{
  "id": 2656783,
  "title": "This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.",
  "url": "https://urgent.news/2026/08/22/this-under-the-radar-healthcare-stock-yields-nearly-8-5-heres-whether-2656783",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-22T21:35:00.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/under-radar-healthcare-stock-yields-213500327.html"
  },
  "original_language": "en",
  "account": "Perrigo (NYSE: PRGO) is a healthcare company that appears stable on the surface, but recent financial performance has been disappointing. The company recently replaced its CEO, leaving a temporary CEO in place while a search for a permanent leader continues.\n\nPerrigo manufactures and sells over-the-counter drugs, and most of its revenue comes from private-label generic drugs. The business model is supposed to be steady, much like other consumer staples companies. However, Perrigo reported weak second-quarter 2026 earnings, with core sales falling 3.1% year over year and organic sales declining 3.5%. Even more concerning, core earnings dropped nearly 21%, to $0.46 per share.\n\nThe company's top line has been trending downwards for over a decade, and its margins have been declining as well. Interim President and Chief Executive Officer Albert Manzone explained that the company is executing its Three-S plan, which includes strengthening areas of the business, improving operational performance, streamlining its portfolio, and reducing debt. However, the streamlining effort may be shrinking the company, as Perrigo is selling non-core assets. The interim CEO noted that proceeds from these sales may be used to reduce debt, but there is also a risk that the company could cut its dividend.\n\nGiven the weak financial performance, shrinking business, and the possibility of a dividend cut, dividend investors should be cautious when considering Perrigo.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.",
        "url": "https://urgent.news/2026/08/22/this-under-the-radar-healthcare-stock-yields-nearly-8-5-heres-whether",
        "published": "2026-08-22T21:15:00.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.",
        "url": "https://urgent.news/2026/08/22/this-under-the-radar-healthcare-stock-yields-nearly-8-5-heres-whether-2662828",
        "published": "2026-08-22T21:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}